Bioventus Launches Osteoarthritis Treatment in Taiwan

Bioventus has launched in Taiwan its single-injection joint fluid Durolane for the treatment of osteoarthritis.

Durolane is indicated for the treatment of mild to moderate osteoarthritis of the knee.

The drug-device combo is based on a technology process called Nasha, which yields stabilized hyaluronic acid, a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. — Michael Cipriano